Invivyd ( (IVVD) ) has released its Q3 earnings. Here is a breakdown of the information Invivyd presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Invivyd, Inc. is a biopharmaceutical company focused on developing monoclonal antibodies for the prevention and treatment of viral infectious diseases, particularly SARS-CoV-2, using a proprietary technology platform.
In its third-quarter 2025 earnings report, Invivyd reported a notable increase in revenue driven by its product PEMGARDA, alongside strategic advancements in its clinical programs, particularly the upcoming pivotal trials for VYD2311, a vaccine-alternative antibody for COVID-19 prevention.
Key financial highlights include a 41% year-over-year increase in PEMGARDA’s net product revenue, reaching $13.1 million, and a strong cash position with over $100 million in cash and equivalents by October 2025. The company also announced the FDA’s clearance for its IND application for VYD2311, setting the stage for the REVOLUTION clinical program, which aims to evaluate the safety and efficacy of this novel antibody.
Strategically, Invivyd is preparing for the commercial launch of VYD2311, pending approval, and is expanding its pipeline to target other pathogens beyond COVID-19. The company also strengthened its leadership team with new appointments and secured significant funding through a public offering.
Looking ahead, Invivyd is positioned to advance its clinical trials and potentially expand its market presence with VYD2311, while continuing to explore opportunities for pipeline expansion beyond SARS-CoV-2.